ANI PHARMACEUTICALS, INC Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
ANI PHARMACEUTICALS, INC (ANIP) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 96.00 thousand shares for the 12-month period ending 2019-12-31, per its 10-K filed 2022-03-15.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2022-03-15
- ANI PHARMACEUTICALS, INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2019-09-30 was 78.00K shares.
- ANI PHARMACEUTICALS, INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2019 was 96.00K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|
| 2019-12-31 | 96.00K shares 10-K · filed 2022-03-15 | ||
| 2019-09-30 | 78.00K shares 10-Q · filed 2020-11-05 | 128.00K shares 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |